Patients can often maintain their weight loss with a lower dose after initial success, which can help balance effectiveness with tolerability. According to Lilly, both trials met their primary and all key secondary endpoints
2 Material and methods This narrative literature review examines the use of SGLT-2 inhibitors and GLP-1 RAs in patients with T2DM and CVD
Autophagy, the cellular mechanism that promotes cell survival during nutrient depletion, may also be relevant under basal or nutrient excess conditions
In addition, we observe higher levels of malondialdehyde (MDA), protein carbonyls and 8-hydroguanosine (8-OHdG) DNA adduct, as hallmarks of cellular lipid, protein and DNA oxidative damage, respectively
Alternatively, a GLP-1RA with proven improvement in CV outcomes can be used if an SGLT-2 inhibitor with evidence for reducing HF or CKD is not tolerated or contraindicated in patients with HF or CKD (
The bottom line on semaglutide and urinary tract infections Semaglutide does not cause UTIs
